scholarly journals Leukemia Inhibitory Factor Influences the Fate Choice of Mesenchymal Progenitor Cells

Stem Cells ◽  
2007 ◽  
Vol 25 (2) ◽  
pp. 305-312 ◽  
Author(s):  
Dominic Falconi ◽  
Kiyoshi Oizumi ◽  
Jane E. Aubin
Keyword(s):  
Progenitor Cells ◽  
Leukemia Inhibitory Factor ◽  
Inhibitory Factor ◽  
Mesenchymal Progenitor Cells

scholarly journals Leukemia inhibitory factor/human interleukin for DA cells: a growth factor that stimulates the in vitro development of multipotential human hematopoietic progenitors

Blood ◽  
1991 ◽  
Vol 77 (2) ◽  
pp. 263-270 ◽  
Author(s):  
C Verfaillie ◽  
P McGlave
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Leukemia Inhibitory Factor ◽  
Colony Growth ◽  
Inhibitory Factor ◽  
Hematopoietic Progenitor ◽  
Bone Marrow Progenitor ◽  
Hla Dr ◽  
Eosinophil Colonies

Abstract We investigated the in vitro hematopoietic stimulatory activity of leukemia inhibitory factor/human interleukin for DA cells (LIF/HILDA) on bone marrow progenitor populations in 17 normal individuals. In serum-free cultures LIF/HILDA did not induce colony growth. In serum containing media, LIF/HILDA stimulated the growth of colony forming unit (CFU)-MIX and CFU-EO in a dose-dependent fashion and resulted in an increased CFU-MIX and burst forming unit-erythrocytes (BFU-E) colony size. Similar stimulatory effects were seen on a highly purified hematopoietic progenitor population obtained after immunomagnetic depletion of mature myeloid precursors and lymphoid cells. Addition of LIF/HILDA to cultures containing maximally stimulatory concentrations of recombinant human interleukin-3 (rhuIL3), rhuIL3 + rhuIL6, or rhu granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) in serum containing media significantly increased the number of CFU-MIX and eosinophil colonies and increased size and cluster number of CFU-MIX and BFU-E. Depletion of accessory T lymphocytes or monocytes from bone marrow progenitors did not alter the response of hematopoietic precursors to LIF/HILDA. A similar increased colony growth was seen when LIF/HILDA was added to cultures of positively selected CD34/HLA- DR+ or CD34+/HLA-DR- bone marrow hematopoietic progenitor cells stimulated with maximally stimulatory concentrations of rhuIL3 + rhuIL6. LIF/HILDA is a novel cytokine capable of stimulating growth and proliferation of multi-lineage, erythroid, and eosinophil colonies in the presence of serum. LIF/HILDA exerts its activity by direct interaction with highly purified immature bone marrow progenitor cells, has an additive effect when used with other cytokines known to stimulate primitive hematopoietic precursors, and does not require accessory cells.

scholarly journals Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice

Blood ◽  
1990 ◽  
Vol 76 (1) ◽  
pp. 50-56 ◽  
Author(s):  
D Metcalf ◽  
NA Nicola ◽  
DP Gearing
Keyword(s):  
Progenitor Cells ◽  
Leukemia Inhibitory Factor ◽  
Blood Platelets ◽  
Marrow Cell ◽  
Inhibitory Factor ◽  
Toxic Effects ◽  
Spleen Weight ◽  
Moderate Increase ◽  
Wide Range

Abstract Purified bacterially synthesized recombinant murine leukemia inhibitory factor (LIF) was injected in varying doses for up to 2 weeks into adult DBA/2 and C3H/HeJ mice. At high doses (2 micrograms, three times daily) LIF exhibited toxic effects seen as behavioral changes, loss of body fat, and thymus atrophy. Dose-related rises were observed in blood platelets, erythrocyte sedimentation rates, and serum calcium to albumin ratios, including dose schedules with no toxic effects. LIF induced a decrease in bone marrow cell numbers, particularly in marrow lymphocytes, and a moderate increase in spleen weight with a reduction in spleen lymphocytes and an elevation of erythroid populations. LIF- injected mice showed a rise in megakaryocytes up to twofold in the marrow and fivefold in the spleen, with an associated 10-fold rise in megakaryocyte progenitor cells in the spleen. Comparable rises in other types of progenitor cells were also observed in the spleen. The observed changes indicate the biologic activity of LIF in vivo and are consistent with the known wide range of in vitro actions of this molecule. The ability of LIF to elevate megakaryocyte and platelet levels suggests a potential clinical application of LIF in the treatment of thrombocytopenias.

scholarly journals Leukemia inhibitory factor/human interleukin for DA cells: a growth factor that stimulates the in vitro development of multipotential human hematopoietic progenitors

Blood ◽  
1991 ◽  
Vol 77 (2) ◽  
pp. 263-270 ◽  
Author(s):  
C Verfaillie ◽  
P McGlave
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Leukemia Inhibitory Factor ◽  
Colony Growth ◽  
Inhibitory Factor ◽  
Hematopoietic Progenitor ◽  
Bone Marrow Progenitor ◽  
Hla Dr ◽  
Eosinophil Colonies

We investigated the in vitro hematopoietic stimulatory activity of leukemia inhibitory factor/human interleukin for DA cells (LIF/HILDA) on bone marrow progenitor populations in 17 normal individuals. In serum-free cultures LIF/HILDA did not induce colony growth. In serum containing media, LIF/HILDA stimulated the growth of colony forming unit (CFU)-MIX and CFU-EO in a dose-dependent fashion and resulted in an increased CFU-MIX and burst forming unit-erythrocytes (BFU-E) colony size. Similar stimulatory effects were seen on a highly purified hematopoietic progenitor population obtained after immunomagnetic depletion of mature myeloid precursors and lymphoid cells. Addition of LIF/HILDA to cultures containing maximally stimulatory concentrations of recombinant human interleukin-3 (rhuIL3), rhuIL3 + rhuIL6, or rhu granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) in serum containing media significantly increased the number of CFU-MIX and eosinophil colonies and increased size and cluster number of CFU-MIX and BFU-E. Depletion of accessory T lymphocytes or monocytes from bone marrow progenitors did not alter the response of hematopoietic precursors to LIF/HILDA. A similar increased colony growth was seen when LIF/HILDA was added to cultures of positively selected CD34/HLA- DR+ or CD34+/HLA-DR- bone marrow hematopoietic progenitor cells stimulated with maximally stimulatory concentrations of rhuIL3 + rhuIL6. LIF/HILDA is a novel cytokine capable of stimulating growth and proliferation of multi-lineage, erythroid, and eosinophil colonies in the presence of serum. LIF/HILDA exerts its activity by direct interaction with highly purified immature bone marrow progenitor cells, has an additive effect when used with other cytokines known to stimulate primitive hematopoietic precursors, and does not require accessory cells.

scholarly journals Effects of injected leukemia inhibitory factor on hematopoietic and other tissues in mice

Blood ◽  
1990 ◽  
Vol 76 (1) ◽  
pp. 50-56 ◽  
Author(s):  
D Metcalf ◽  
NA Nicola ◽  
DP Gearing
Keyword(s):  
Progenitor Cells ◽  
Leukemia Inhibitory Factor ◽  
Blood Platelets ◽  
Marrow Cell ◽  
Inhibitory Factor ◽  
Toxic Effects ◽  
Spleen Weight ◽  
Moderate Increase ◽  
Wide Range

Purified bacterially synthesized recombinant murine leukemia inhibitory factor (LIF) was injected in varying doses for up to 2 weeks into adult DBA/2 and C3H/HeJ mice. At high doses (2 micrograms, three times daily) LIF exhibited toxic effects seen as behavioral changes, loss of body fat, and thymus atrophy. Dose-related rises were observed in blood platelets, erythrocyte sedimentation rates, and serum calcium to albumin ratios, including dose schedules with no toxic effects. LIF induced a decrease in bone marrow cell numbers, particularly in marrow lymphocytes, and a moderate increase in spleen weight with a reduction in spleen lymphocytes and an elevation of erythroid populations. LIF- injected mice showed a rise in megakaryocytes up to twofold in the marrow and fivefold in the spleen, with an associated 10-fold rise in megakaryocyte progenitor cells in the spleen. Comparable rises in other types of progenitor cells were also observed in the spleen. The observed changes indicate the biologic activity of LIF in vivo and are consistent with the known wide range of in vitro actions of this molecule. The ability of LIF to elevate megakaryocyte and platelet levels suggests a potential clinical application of LIF in the treatment of thrombocytopenias.

Sign in / Sign up

Export Citation Format

Share Document